Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 326 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Lung Cancer, Melanoma (Skin)
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
Conditions
SARS CoV 2 Infection, COVID-19
Interventions
Pfizer/BioNTech (BNT162b2), Moderna
Biological
Lead sponsor
DHR Health Institute for Research and Development
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
Conditions
COVID-19
Interventions
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
3,159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Universal Anti-Viral Vaccine for Healthy Elderly Adults

NCT04441047
Conditions
Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia, Influenza, Human, ARDS, Human
Interventions
AlloStim
Drug
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Delray Beach, Florida • Miami, Florida • Tampa, Florida + 1 more
Conditions
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Interventions
9vHPV Vaccine, mRNA-1273 Vaccine
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
9 Years to 11 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

NCT05089565
Conditions
Sarcoidosis, SARS-CoV2 Infection, Vaccine Response Impaired
Interventions
Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
COVID-19 Vaccines
Interventions
Reminder/Recall Sent Via Preferred Method of Communication
Behavioral
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
12 Years to 17 Years
Enrollment
4,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Marshfield, Wisconsin
Terminated Not applicable Interventional Accepts healthy volunteers

Multilevel Intervention of COVID-19 Vaccine Uptake Among Latinos

NCT06156228
Conditions
Vaccine Hesitancy
Interventions
Multilevel Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Diego, California
Enrolling by invitation Not applicable Interventional

Patient-Centered Practical Vaccine Talk For Busy Clinicians

NCT07651761
Conditions
Influenza, COVID-19
Interventions
Provider communication training
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
24,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

COVID-19 Reactogenicity

NCT07051031
Conditions
COVID-19
Interventions
Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
Drug
Lead sponsor
Marcel Curlin
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of NVX-CoV2705

NCT07079670
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
NVX-CoV2705
Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 90 Years
Enrollment
676 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more
Conditions
COVID-19 Vaccine Knowledge, COVID-19 Vaccine Beliefs
Interventions
COVID-19 Vaccine IVR Training, Control Condition
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8,959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Conditions
SARS-CoV-2
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy Volunteer
Interventions
Flucelvax, Fluvirin, Fluzone High Dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Novelty, Conformity and Trust in COVID-19 Vaccines

NCT04693689
Conditions
Trust
Interventions
RNA vaccine, 20% adoption rate, 40% adoption rate, 60% adoption rate, 80% adoption rate, Conventional vaccine, 0% adoption rate
Other
Lead sponsor
National University of Singapore
Other
Eligibility
18 Years and older
Enrollment
35,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Mateo, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Messaging for Vaccination

NCT05182554
Conditions
Vaccination Refusal, COVID-19 Pandemic
Interventions
Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
Behavioral
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Terminated Not applicable Interventional Accepts healthy volunteers

Motivational Interviewing for Vaccine Uptake in Latinx Adults

NCT06062056
Conditions
Vaccine Hesitancy
Interventions
EHR alert, Motivational Interviewing, Warm hand off to nurse
Other · Behavioral
Lead sponsor
Boston College
Other
Eligibility
18 Years and older
Enrollment
3,698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions
Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug
Biological · Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 4 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276
Conditions
Covid-19 Prevention
Interventions
Ad26.COV2.S, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of NVX-CoV2705

NCT07086222
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
NVX-CoV2705, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
50 Years to 65 Years
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
99
States / cities
Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
Conditions
Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
Interventions
COVID-19 serology IgG
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan